HER3, p95HER2, and HER2 protein expression levels define multiple subtypes of HER2-positive metastatic breast cancer

Trastuzumab is effective in the treatment of HER2/neu over-expressing breast cancer, but not all patients benefit from it. In vitro data suggest a role for HER3 in the initiation of signaling activity involving the AKT–mTOR pathway leading to trastuzumab insensitivity. We sought to investigate the p...

Descripción completa

Detalles Bibliográficos
Autores principales: Lipton, Allan, Goodman, Laurie, Leitzel, Kim, Cook, Jennifer, Sperinde, Jeff, Haddad, Mojgan, Köstler, Wolfgang J., Huang, Weidong, Weidler, Jodi M., Ali, Suhail, Newton, Alicia, Fuchs, Eva-Marie, Paquet, Agnes, Singer, Christian F., Horvat, Reinhard, Jin, Xueguang, Banerjee, Joyee, Mukherjee, Ali, Tan, Yuping, Shi, Yining, Chenna, Ahmed, Larson, Jeff, Lie, Yolanda, Sherwood, Thomas, Petropoulos, Christos J., Williams, Stephen, Winslow, John, Parry, Gordon, Bates, Michael
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer US 2013
Materias:
Preclinical Study
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3758835/
https://www.ncbi.nlm.nih.gov/pubmed/23959396
http://dx.doi.org/10.1007/s10549-013-2665-0

Ejemplares similares

Ejemplares similares